We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-2.86%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.1B
AUM Growth
-$432M
Cap. Flow
-$290M
Cap. Flow %
-26.37%
Top 10 Hldgs %
65.53%
Holding
227
New
63
Increased
36
Reduced
51
Closed
66

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$19.5M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$7.96M
3
MNKD icon
MannKind Corp
MNKD
+$4.94M
4
ESPR
Esperion Therapeutics
ESPR
+$3.17M
5
BNBX
BNB PLUS CORP
BNBX
+$2.81M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$3.35M
2
BMY icon
Bristol-Myers Squibb
BMY
+$3.2M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$2.96M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$2.32M
5
HURA
TuHURA Biosciences
HURA
+$1.78M

Sector Composition

Rank Sector Weight
1 Healthcare 11.87%
2 Financials 0.19%
3 Industrials 0.07%
4 Consumer Staples 0.03%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
26
PUT
DELISTED
bluebird bio
BLUE
$8.64M 0.79%
37
-7
-16% -$14.2K
SRPT icon
27
PUT
Sarepta Therapeutics
SRPT
$1.63B
$8.19M 0.75%
1,472
+954
+184% +$50.5K
ABBV icon
28
PUT
AbbVie
ABBV
$465B
$7.5M 0.68%
+776
New +$73.1K
VRTX icon
29
PUT
Vertex Pharmaceuticals
VRTX
$124B
$7.28M 0.66%
486
-771
-61% -$114K
IONS icon
30
CALL
Ionis Pharmaceuticals
IONS
$9.14B
$7.19M 0.65%
1,429
+6
+0.4% +$329
IONS icon
31
PUT
Ionis Pharmaceuticals
IONS
$9.14B
$6.19M 0.56%
1,230
-382
-24% -$20.9K
SAGE
32
CALL
DELISTED
Sage Therapeutics
SAGE
$5.76M 0.53%
350
-352
-50% -$34.1K
ONCE
33
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$5.7M 0.52%
+110,827
New +$7.96M
XNTK icon
34
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2B
$5.57M 0.51%
+656
New +$54.7K
INCY icon
35
CALL
Incyte
INCY
$26B
$5.04M 0.46%
532
+150
+39% +$15.7K
RDUS
36
CALL
DELISTED
Radius Health, Inc.
RDUS
$4.88M 0.44%
+1,536
New +$48.2K
GWPH
37
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$4.66M 0.42%
353
-796
-69% -$93.5K
SGMO
38
PUT
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.48M 0.41%
2,730
+2,155
+375% +$32.1K
ZGNX
39
PUT
DELISTED
Zogenix, Inc.
ZGNX
$4.46M 0.41%
1,114
-161
-13% -$6.19K
SAGE
40
PUT
DELISTED
Sage Therapeutics
SAGE
$4.27M 0.39%
+259
New +$25.1K
MNKD icon
41
MannKind Corp
MNKD
$1.21B
$3.36M 0.31%
+1,446,900
New +$4.94M
NKTR icon
42
CALL
Nektar Therapeutics
NKTR
$2.39B
$3.33M 0.3%
+37
New +$21.9K
GILD icon
43
CALL
Gilead Sciences
GILD
$167B
$3.25M 0.3%
454
– –
ALXN
44
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$2.95M 0.27%
+247
New +$30.1K
FOLD
45
PUT
DELISTED
Amicus Therapeutics
FOLD
$2.88M 0.26%
2,000
+1,500
+300% +$20.6K
OTLK icon
46
Outlook Therapeutics
OTLK
$169M
$2.7M 0.25%
12,996
-1,904
-13% -$395K
ABBV icon
47
AbbVie
ABBV
$465B
$2.67M 0.24%
+27,559
New +$2.6M
ICPT
48
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.61M 0.24%
447
+347
+347% +$21.9K
ALNY icon
49
Alnylam Pharmaceuticals
ALNY
$38.5B
$2.45M 0.22%
+19,250
New +$2.42M
AMAG
50
PUT
DELISTED
AMAG Pharmaceuticals
AMAG
$2.41M 0.22%
1,822
-1,182
-39% -$17.8K
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sabby Management held 227 positions worth $1.1B, down 28% from $1.53B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management withdrew a net $290M in Q4 2017, closing 66 positions and reducing 51 holdings. Its most notable exit was GW Pharmaceuticals Plc American Depositary Shares, an estimated $3.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 7.3% a quarter earlier, followed by Financials and Industrials.

Against the trend, Sabby Management opened a new position in Odonate Therapeutics, Inc. Common Stock worth $20.6M.

  • Sabby Management's largest Q4 2017 buy was Odonate Therapeutics, Inc. Common Stock: 825,451 shares worth $20.6M.
  • Sabby Management added most to Esperion Therapeutics in Q4 2017, an estimated $3.17M increase.
  • Sabby Management's biggest Q4 2017 reduction was Bristol-Myers Squibb, cutting an estimated $3.2M.
  • Sabby Management fully exited GW Pharmaceuticals Plc American Depositary Shares in Q4 2017, selling an estimated $3.35M.
  • Sabby Management's ten largest holdings make up 66% of its $1.1B portfolio in Q4 2017.
  • Sabby Management opened 63 new positions and closed 66 in Q4 2017.
  • Sabby Management's portfolio value fell 28% quarter-over-quarter to $1.1B.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.